GlycoMimetics Announces Strategic Review and Restructuring Plan
Company Announcements

GlycoMimetics Announces Strategic Review and Restructuring Plan

GlycoMimetics (GLYC) just unveiled an update.

GlycoMimetics, Inc. is implementing a new operating plan to enhance shareholder value, which includes a strategic review and a reduction of its workforce by 80%. The decision comes after the FDA suggested an additional clinical trial for their lead drug, uproleselan. The company expects to record around $3.6 million in charges due to the layoffs, predominantly for severance and benefits, with most costs recognized in the third quarter of 2024. Additionally, the company’s Chief Medical Officer, Dr. Edwin Rock, will depart, with a severance package and a consulting agreement in place for post-separation services.

For a thorough assessment of GLYC stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyGlycoMimetics options imply 8.8% move in share price post-earnings
TheFlyBiotech Alert: Searches spiking for these stocks today
TheFlyBiotech Alert: Searches spiking for these stocks today
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App